Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635102 · ClinicalTrials.gov registry record · NA
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT00635102 is a NA study that has completed, run by Yale University. The registered enrollment target is 57 participants.
The verdict
NCT00635102, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
Question #1: Will glycine ameliorate cognitive deficits? Hypothesis #1: Based on positive findings conducted with glycine and milacemide, a glycine prodrug, in schizophrenia and dementia, we expect that glycine will ameliorate cognitive deficits. Question #2: Will alcoholic patients show enhanced endocrinal effects to glycine? Hypothesis #2: Based on the dose-related effects of glycine in healthy subjects, we expect that glycine will increase the endocrinal response to glycine in alcoholic patients with, supposedly, dysregulated NMDA receptor function. Question #3: Will D-cycloserine have ethanol-like effects? Hypothesis #3: If inhibition of NMDA receptor function is fundamental to the subjective effects of ethanol, then the NMDA antagonist properties of D-cycloserine should be recognized as ethanol-like (relative to placebo) in recently detoxified alcoholics and healthy subjects. Question #4: Will D-cycloserine reverse cognitive benefits of glycine? Hypothesis 4: Based on the dose related NMDA antagonist activity of D-cycloserine, we expect that D-cycloserine will compete with the agonist activity of glycine and therefore it will reverse the cognitive benefits of glycine. Question #5: Will D-cycloserine inhibit endocrinal effects of glycine? Hypothesis #5: If the agonist activity of glycine is necessary to determine endocrine response, then the dose-related NMDA antagonist properties of D-cycloserine should block these effects.
Interventions
- DRUG D-Cycloserine PO and Glycine IV
- DRUG Placebo D-Cycloserine PO and placebo Glycine IV
- DRUG Placebo D-Cycloserine PO and Glycine IV
- DRUG D-Cycloserine PO and placebo Glycine IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 1997-10 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635102
The ClinicalTrials.gov registry entry for NCT00635102 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which D-Cycloserine PO and Glycine IV is the first listed.
NCT00635102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635102 about?
NCT00635102 is a clinical study titled "Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects". Question #1: Will glycine ameliorate cognitive deficits? Hypothesis #1: Based on positive findings conducted with glycine and milacemide, a glycine prodrug, in schizophrenia and dementia, we expect that glycine will ameliorate cognitive deficits. Question #2: Will alcoholic patients show enhanced e...
What is the current status of trial NCT00635102?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 1997-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00635102?
The interventions under investigation include: D-Cycloserine PO and Glycine IV (DRUG), Placebo D-Cycloserine PO and placebo Glycine IV (DRUG), Placebo D-Cycloserine PO and Glycine IV (DRUG), D-Cycloserine PO and placebo Glycine IV (DRUG).
Who is sponsoring clinical trial NCT00635102?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.